A regional analysis of epidermal growth factor rec

Authors: D Kelly L Mc Sorley E O’Shea E Mc Carthy S Bowe C Brady J Sui M A Dawod O O’Brien D Graham J McCarthy L Burke D Power S O’Reilly R M Bambury D O Mahony

Publish Date: 2017/02/09

Volume: 186, Issue: 4, Pages: 855-857

PDF Link

Abstract

EGFR mutated lung cancer represents a subgroup with distinct clinical presentations prognosis and management requirements We investigated the survival prognostic factors and realworld treatment of NSCLC patients with EGFR mutation in clinical practiceA retrospective review of all specimens sent for EGFR analysis from December 2009 to September 2015 was performed Patient demographics specimen type EGFR mutation status/type stage at diagnosis treatment response rate and survival data were recorded27/334 8 patient specimens sent for EGFR testing tested positive for a sensitising EGFR mutation The median age was 65 years 40–85 years Exon 19 deletion represented the most commonly detected alteration accounting for 39 n = 11 Firstline treatment for those with Exon 18 19 or 21 alterations n = 24 was with an EGFR tyrosine kinase inhibitor TKI in 79 n = 19 Objective response rate among these patients was 74 and median duration of response was 13 months range 7–35 monthsThe incidence of EGFR mutation in our cohort of NSCLC is 9 which is consistent with mutation incidence reported in other countries The rate of EGFR mutation in our population is slightly below that reported internationally but treatment outcomes are consistent with published data Realworld patient data have important contributions to make with regard to quality measurement incorporating patient experience into guidelines and identifying safety signalsThere are no conflicts of interest to declare D Kelly declares that she has no conflict of interest L Mc Sorley declares that she has no conflict of interest E O’Shea declares that he has no conflict of interest E Mc Carthy declares that she has no conflict of interest S Bowe declares that she has no conflict of interest C Brad y declares that she has no conflict of interest J Sui declares that she has no conflict of interest M A Dawod declares that he has no conflict of interest O O’Brien declares that he has no conflict of interest D Graham declares that she has no conflict of interest J McCarthy declares that she has no conflict of interest L Burke declares that she has no conflict of interest D Power declares that he has no conflict of interest S O’Reilly declares that he has no conflict of interest R M Bambury declares that he has no conflict of interest D O Mahony declares that she has no conflict of interestAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards

Keywords: